Polysaccharide Patents (Class 514/54)
-
Patent number: 9816122Abstract: The invention relates to a method for producing a glycoconjugate comprising an oligosaccharide part covalently linked to a non-sugar moiety selected from the group consisting of amino acids, peptides, proteins, lipids, longer alkyl groups, polyethylene glycols, ?,?-unsaturated amido group and polyvinyl alcohols, using a genetically modified cell.Type: GrantFiled: September 25, 2013Date of Patent: November 14, 2017Assignee: Glycom A/SInventors: Pauline Peltier-Pain, Gyula Dekany, Christophe Pain, Pierre Chassagne, Nicolas Fierfort, Dóra Molnàr-Gàbor
-
Patent number: 9808482Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered its exclusive capacity in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, HIV, Cytomegalovirus and the virus of vesicular stomatitis.Type: GrantFiled: May 11, 2010Date of Patent: November 7, 2017Assignee: FIDIA FARMACEUTICI S.p.A.Inventors: Devis Galesso, Anna Maria Zanellato
-
Patent number: 9801899Abstract: The present invention relates to an oil-in-water emulsion comprising at least one mucomimetic polymer, at least one lipid of phospholipid type, at least one lipid other than the phospholipid, at least one stabilizing polymer, and a hydrophilic liquid, to an emulsion comprising an aqueous phase that contains at least one stabilizing polymer and at least one mucomimetic polymer, and an oily phase that contains at least one lipid of phospholipid type and a lipid other than the phospholipid, to a medicament comprising one of these emulsions, and to the use of one of these emulsions as an agent for restoring and/or replacing the lachrimal film or as a carrier for an active compound.Type: GrantFiled: April 21, 2011Date of Patent: October 31, 2017Assignee: Horus PharmaInventors: Claude Claret, Martine Claret, Carole Gard, Nicola Lamprecht-Weissenborn
-
Patent number: 9801400Abstract: Compositions comprising cellulosic polymers and natural honey that display reduced instability due to the presence of a chelant that inhibits the activity of naturally occurring cellulases are described. Methods of treating natural honey to inhibit cellulase activity comprising mixing the natural honey with a chelant and optionally heating the mixture are provided. Flavor compositions consisting of natural honey and a chelant, optionally in a carrier are further described.Type: GrantFiled: June 9, 2008Date of Patent: October 31, 2017Assignee: The Procter & Gamble CompanyInventors: Nicholas James Cummins, Jayant Eknath Khanolkar, Vasiliki Poulopoulou, Vaishali Shailendra Rane
-
Patent number: 9789124Abstract: A method for reducing the frequency of urination is disclosed. The method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents and one or more ?-blockers. In one embodiment, the one or more analgesic agents are formulated for extended-release.Type: GrantFiled: July 31, 2015Date of Patent: October 17, 2017Assignee: WELLESLEY PHARMACEUTICALS, LLCInventors: David A. Dill, Ilya A. Volfson
-
Patent number: 9789226Abstract: Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.Type: GrantFiled: February 16, 2016Date of Patent: October 17, 2017Assignee: TeoxaneInventors: Francois Bourdon, Stephane Meunier
-
Patent number: 9763973Abstract: The present invention provides a or therapeutic agent for HAM, containing pentosan polysulfate or a pharmaceutically acceptable salt thereof as an active ingredient. The present invention also provides an agent for improving a HAM-associated movement disorder, containing pentosan polysulfate or a pharmaceutically acceptable salt thereof as an active ingredient.Type: GrantFiled: October 12, 2012Date of Patent: September 19, 2017Assignees: Nagasaki University, ReqMed Company, Ltd.Inventors: Tatsufumi Nakamura, Tadashi Matsumoto
-
Patent number: 9763974Abstract: Aspects of the invention provide methods for treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases. In particular, aspects of the invention relate to the use of a therapeutic formulation comprising a galacto-rhamnogalacturonate for the treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases.Type: GrantFiled: June 6, 2013Date of Patent: September 19, 2017Assignee: Galectin Therapeutics, Inc.Inventors: Peter G. Traber, Eliezer Zomer, Anatole A. Klyosov
-
Patent number: 9763466Abstract: A carbohydrate mixture for dietetic foods and pharmaceuticals is provided. The carbohydrate mixture comprises two different, substantially soluble carbohydrate components A and B, which remain undigested in the gastrointestinal tract and enter the large intestine without being resorbed. Carbohydrate component A may comprise at least one monosaccharide or of at least one oligosaccharide (disaccharide to hexasaccharide) or a mixture of two or more of these saccharides. Carbohydrate component B may comprise a polysaccharide (from heptasaccharide onwards) or a mixture of two or more polysaccharides. Carbohydrate component A=5 to 95 wt-% and carbohydrate component B=5 to 95 wt-% of the sum of the carbohydrate components A+B (=100 wt-%), and at least 80 wt-% of the carbohydrates/saccharides of both carbohydrate components have a prebiotic effect. The carbohydrate mixtures have not only a nutritive effect but they also stimulate health-promoting microorganisms present in the natural flora of the large intestine.Type: GrantFiled: October 7, 2013Date of Patent: September 19, 2017Assignee: N.V. NutriciaInventors: Gunther Sawatzki, Bernd Stahl
-
Patent number: 9730887Abstract: The present invention relates to an injectable aqueous viscous solution for treating varicose veins. It also relates to a catheter system with cannulas for vascular puncture with double or triple cut tip comprising, (i) an outer cannula (non-cutting element), a tube-like construction which is slightly flexible, (a) the tip zone being tapered to ease introduction, (b) the edges being optionally rounded to provide atraumatic advancement (c) optionally with a Luer-lock connector (ii) a hollow needle which is flexible and bendable (c) optionally with a transparent flashback chamber, wherein (d) the diameter of the needle is below the diameter of the catheter, wherein (iii) the needle and outer cannula are connected by a temporary lock to ensure the needle tip is fixed in adequate position outside the outer cannula outer cannula during skin puncture and introduction towards the target region.Type: GrantFiled: December 20, 2012Date of Patent: August 15, 2017Assignee: Angioclinic AGInventor: Johann Christof Ragg
-
Patent number: 9717753Abstract: The present invention provides a lubricating composition comprising an alginic acid or a salt or ester thereof, which is effective in reducing frictions in artificial joints and wear of artificial joint implants. Also provided is a method for lubricating artificial joints comprising administering said composition to a synovial cavity of a subject. In another aspect, the present invention provides use of an alginic acid or a salt or ester thereof in manufacturing a lubricating composition.Type: GrantFiled: November 14, 2014Date of Patent: August 1, 2017Assignee: National Taipei University of TechnologyInventors: Hsu-Wei Fang, Shu-Wen Chen, Yi-Ling Huang
-
Patent number: 9687558Abstract: The present invention describes a new group of bioconjugates which can be obtained by means of indirect synthesis, via a molecular spacer, between hyaluronic acid and/or its derivatives and drugs with an antitumoral activity belonging to different groups, their preparation process and use in the oncological field. The new derivatives, in relation to the type of bond and Substitution degree, have different physico-chemical properties which improve their tolerability and efficiency and allow a more accurate modulation of the dosage, exploiting an active targeting mechanism.Type: GrantFiled: August 2, 2006Date of Patent: June 27, 2017Assignee: FIDIA FARMACEUTICI S.P.A.Inventors: Davide Renier, Fabio Bettella
-
Patent number: 9662424Abstract: A biocompatible membrane comprised of alginate and hyaluronate. The membrane may be used to prevent unwanted scarring after surgery. The tissue adherence and the rate of bioresorption of the membrane may be modified through an external stimulus comprising a sequestering agent and a viscosity modifier.Type: GrantFiled: December 11, 2013Date of Patent: May 30, 2017Assignee: Board of Regents, The University of Texas SystemInventors: Christine E. Schmidt, Scott A. Zawko, Sarah M. Mayes
-
Patent number: 9662350Abstract: A pharmaceutical composition for inhibiting inflammation is provided. The pharmaceutical composition comprises (a) hyaluronic acid, (b) a vitamin and (c) a pharmaceutically acceptable carrier.Type: GrantFiled: August 6, 2014Date of Patent: May 30, 2017Assignee: CHINA MEDICAL UNIVERSITYInventors: Feng-Huei Lin, Teng-Le Huang, Horng-Chaung Hsu, Chun-Hsu Yao, Yueh-Sheng Chen, Wen-Yu Su
-
Patent number: 9649329Abstract: Administration of low molecular weight (10,000-20,000 Daltons, or lower) pectins, particularly modified citrus pectins (MCP), like PectaSol-C reduces galectins-3 levels in vivo. Reduction of galectin-3 levels by MCP inhibits inflammation, inhibits fibrosis formation in organs and tissues, and inhibits cancer formation, progression, transformation and metastases. The reduction in circulating, serum and cellular galectin-3, inherently resulting from the administration of MCP, provides benefit over a spectrum of biological conditions, as evidenced by in vivo trials.Type: GrantFiled: July 20, 2016Date of Patent: May 16, 2017Assignee: ecoNugenics, Inc.Inventor: Isaac Eliaz
-
Patent number: 9650244Abstract: Disclosed are drug delivery systems and methods for extravascular administration of drug, vaccine, and/or diagnostic agents, for use in research and medical applications.Type: GrantFiled: August 25, 2011Date of Patent: May 16, 2017Assignee: Genesegues, Inc.Inventor: Gretchen Unger
-
Patent number: 9642914Abstract: A photocrosslinked biodegradable hydrogel includes a plurality of natural polymer macromers cross-linked with a plurality of hydrolyzable acrylate cross-links. The hydrogel is cytocompatible and produces substantially non-toxic products upon degradation.Type: GrantFiled: August 31, 2012Date of Patent: May 9, 2017Assignee: Case Western Reserve UniversityInventors: Eben Alsberg, Oju Jeon
-
Patent number: 9636290Abstract: The invention relates to cosmetic or dermatological compositions containing mannoproteins as an active ingredient and/or adjuvant, to the use of said cosmetic or dermatological compositions and to cosmetic treatment methods.Type: GrantFiled: September 23, 2008Date of Patent: May 2, 2017Assignee: LESAFFRE ET COMPAGNIEInventors: Peter Jüsten, Dominique Marie Noëlle Borreill
-
Patent number: 9632074Abstract: In alternative embodiments, the invention provides compositions and methods for overcoming or diminishing or preventing Growth Factor Inhibitor resistance in a cell, or, a method for increasing the growth-inhibiting effectiveness of a Growth Factor inhibitor on a cell, or, a method for re-sensitizing a cell to a Growth Factor Inhibitor, comprising for example, administration of a combination of a TBK1 inhibitor and an RTK inhibitor. In alternative embodiments, the cell is a tumor cell, a cancer cell or a dysfunctional cell.Type: GrantFiled: July 7, 2014Date of Patent: April 25, 2017Assignee: The Regents of the University of CaliforniaInventors: David Cheresh, Laetitia Seguin, Sudarshan Anand
-
Patent number: 9629386Abstract: The present invention can provide a nutrition composition useful for patients with renal diseases, which has an effective prophylactic or improving effect for various symptoms of malnutrition, inflammation, arteriosclerosis, abnormal lipid metabolism and oxidative stress, associated with renal diseases, or for diabetic nephropathy. The nutrition composition of the present invention m contains one or more kinds of free amino acids selected from the group consisting of valine, leucine, isoleucine and histidine, and a lipid comprising ?-3 fatty acid and ?-6 fatty acid at a weight ratio (?-6 fatty acid to ?-3 fatty acid) of 0.5-5.5. In addition, the composition further contains a soybean protein or a hydrolysate thereof together with the aforementioned lipid or instead of the aforementioned lipid.Type: GrantFiled: June 3, 2011Date of Patent: April 25, 2017Assignee: AJINOMOTO CO., INC.Inventors: Shinji Somekawa, Tomoyuki Mine, Naoki Hayashi
-
Patent number: 9623043Abstract: The present invention relates to a glucan having a weight average molar mass of 15,000 to 50,000 g/mol on a single chain basis and a weight average molar mass in aqueous solution on an aggregate basis of 4 to 20×105 g/mol and existing in gel form in aqueous solution at a concentration ?1% at 25° C. and neutral pH and having a melting temperature (gel to sol) of 30 to 44° C. when the glucan is dissolved in water at a concentration of 2%, methods for the production thereof, medical uses thereof, physical supports having the glucan applied thereto or impregnated thereon and in vitro methods of proliferation of skin cells which comprise contacting a population of skin cells with the glucan.Type: GrantFiled: November 29, 2011Date of Patent: April 18, 2017Assignee: BIOTEC PHARMACON ASAInventors: Rolf Engstad, Thor Nøkland
-
Patent number: 9623042Abstract: The invention relates to a combination preparation for improving the sperm quality and capacitation of a male individual. Said combination preparation comprises effective amounts of L-carnitine, coenzyme Q10, at least one vitamin E, particularly ?-tocopherol, at least one source of zinc, especially zinc sulfate or zinc chloride, at least one source of vitamin B, particularly folic acid, at least one source of selenium, glutathione, and arginine or salts or derivatives thereof as active substances.Type: GrantFiled: February 5, 2007Date of Patent: April 18, 2017Assignee: Fapa Vital AnstaltInventor: Brigitte Annerl
-
Patent number: 9616016Abstract: A composition includes at least one fatty acid glycerol ester for use during or after a vitrectomy procedure, the composition being bioresorbable, being injectable in the vitreous cavity, having a density below 1, more preferably between 0.90 and 1, or a density above 1, more preferably between 1 and 1.5; having a surface tension of less than 50 dynes/cm more preferably ranging from 20 and 30 dynes/cm, being not susceptible to emulsify into droplets when injected; method for treating a retinal disorder involving the use of the composition.Type: GrantFiled: November 19, 2010Date of Patent: April 11, 2017Assignee: SANTEN SASInventors: Frédéric Lallemand, Jean-Sébastien Garrigue, Jeffrey Heier
-
Patent number: 9603890Abstract: Disclosed are compositions and methods for triggering disease selective macropinocytosis. The compositions can serve as a marker of disease activity and as a trigger of enhanced macropinocytosis in tissues undergoing disease remodeling such as wound healing, cancer, PAH, inflammation, diabetes, Crohn's disease, ulcerative colitis, ankylosing spondylitis, diseases of the endometrium, psoriasis, irritable bowel syndrome, arthritis, fibrotic disorders, interstitial cystitis, autoimmune diseases, asthma, acute lung injury, and adult respiratory distress syndrome. The compositions can also serve as a receptor for disease selective cell penetrating peptides in the cells and extracellular matrix of diseased tissues.Type: GrantFiled: December 3, 2013Date of Patent: March 28, 2017Assignee: Vascular BiosciencesInventor: David Mann
-
Patent number: 9597349Abstract: There is provided a wound healing composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin in association with a pharmaceutically acceptable carrier. In addition, a method of topically treating wounds using at least one oxidant and at least one photoactivator capable of activating the oxidant followed by illumination of said photosensitizer is disclosed.Type: GrantFiled: November 11, 2014Date of Patent: March 21, 2017Assignee: KLOX Technologies Inc.Inventors: Remigio Piergallini, Nikolaos Loupis, Francesco Bellini
-
Patent number: 9598505Abstract: The present invention relates to novel silyl-derivatives of polysaccharides and their salts, the processes for their preparation and their use in cosmetic/pharmaceutical field.Type: GrantFiled: March 4, 2011Date of Patent: March 21, 2017Assignee: SILDEHA SIXASS S.A.Inventors: Gaspare Aita, Demetrio Manenti, Pasqualino Rossi, Giuseppe Rosano
-
Patent number: 9585828Abstract: The present invention was made in view of an object to produce a novel proteoglycan-containing material, and find a novel use and/or a superior effect of the proteoglycan-containing material. The present invention provides a proteoglycan-containing material obtained from fish cartilage, wherein the proteoglycan-containing material comprises an acidic saccharide component having a molecular weight of not less than 2000 kDa. The proteoglycan-containing material provides advantageous effects for skin-moisturizing and skin anti-aging, including a superior skin fibroblast proliferation effect, an effect of enhancing and improving the skin barrier function, an effect of enhancing and improving the skin's capability to produce collagen, a dermis-thickening inhibition effect, and the like.Type: GrantFiled: October 4, 2013Date of Patent: March 7, 2017Assignees: SUNSTAR INC., HIROSAKI UNIVERSITYInventors: Masashi Goto, Kazushi Yamamoto, Youji Katou, Yohtaro Katagata, Seiko Itou
-
Patent number: 9579388Abstract: A system for alleviating the appearance of scar tissue, said system comprising a combination of two compounds; a first compound having properties that perform skin regeneration; and a second compound having properties that provide a physical barrier adapted to protect scar tissue by insulating it from ambient air while maintaining and protecting said first compound that is combined therewith.Type: GrantFiled: November 29, 2012Date of Patent: February 28, 2017Inventors: Rene Gauthier, Claude Marquis
-
Patent number: 9579300Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.Type: GrantFiled: February 20, 2014Date of Patent: February 28, 2017Assignee: NANOPHARMACEUTICALS LLCInventors: Shaker A. Mousa, Faith B. Davis, Paul J. Davis
-
Patent number: 9573919Abstract: The present invention provides a peroxisome proliferator-activated receptor (PPAR) activator, which is free from the problem of side effects, can be taken over a long term and has no characteristics taste. Nobiletin is employed as a PPAR activator. Nobiletin has an excellent PPAR activity and has an excellent adiponectin secretion-promoting effect, and is contained in a large amount in citrus fruits, in particular, in Shiikuwasha (Citrus depressa HAYATA) indigenous to Okinawa (Japan). Since citrus fruits have been consumed for many years, the safety of nobiletin has been proven and besides, nobiletin has a low calorie content. Therefore, it can be taken over a long term. Moreover, because of being tasteless and odorless, nobiletin would not damage the unique taste of a food when added thereto. Therefore, it can be added to foods and taken.Type: GrantFiled: May 7, 2007Date of Patent: February 21, 2017Assignee: ARKRAY, Inc.Inventor: Takao Sasaki
-
Patent number: 9566297Abstract: The present invention provides compositions and methods to inhibit fibrosis and scarring associated with surgery. The present invention relates to the discovery that a synthetic anionic polymer consisting of dextran-sulfate (anionic carbohydrate) conjugated to Tirofiban (an anti-platelet agent which prevents platelet activation and aggregation) can effectively inhibit adhesions that form during surgery. This application is a continuation in part to U.S. patent application Ser. No. 13/202,006. The novel biocompatible conjugate compound of the original application can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that the conjugate compound effectively inhibits the invasion of cells which is associated with detrimental healing processes without affecting platelet populations. Use of any of several different anionic components with any of several different anti-platelet agents results in many different specific embodiments of the invention.Type: GrantFiled: March 24, 2014Date of Patent: February 14, 2017Assignee: Novelmed Therapeutics, Inc.Inventor: Rekha Bansal
-
Patent number: 9566298Abstract: The present invention provides methods for treating acute kidney injury through introduction of one or more drag reducing polymers, oligomers, and/or monomers, as well as compositions that include therapeutic amounts of one or more of these drag reducing polymers, oligomers, and/or monomers. These compositions may also include additional components that enhance at least one of the stability, effectiveness, or administerability of the polymers, oligomers, and/or monomers—such as buffers, anti-oxidants, and enzyme inhibitors.Type: GrantFiled: June 30, 2015Date of Patent: February 14, 2017Assignee: HemaFlo Therapeutics Inc.Inventor: Dale R. Peterson
-
Patent number: 9561166Abstract: A personal or household care product includes cationic, nonionic or cationic/nonionic derivatized polysaccharide in combination with a phosphate ester surfactant. The derivatized polysaccharide polymer is formed by reacting the polysaccharide ester surfactant for a sufficient time and at a sufficient temperature in the presence of water, caustic, and at least one surfactant. The polysaccharide polymer may optionally be reacted with an oxidizing agent, hydrolytic or proteolytic enzymes, molecular weight reducing agents and a cationizing agent and nonionic agent. The formed derivatized polysaccharide has a lower clarity in water than in an aqueous surfactant system.Type: GrantFiled: February 20, 2012Date of Patent: February 7, 2017Assignee: HERCULES INCORPORATEDInventors: Anita N. Chan, Louis Patrick Dziuk, Jr., Paquita Erazo-Majewicz, Jashawant J. Modi, M. Olaf Michelson, Bruce Kevin Fillipo, Nabil Naouli
-
Patent number: 9546361Abstract: Described herein are proteins having lyase activity and nucleic acid sequences which code therefor; along with methods of expressing, isolating, purifying, and using same.Type: GrantFiled: October 11, 2013Date of Patent: January 17, 2017Assignee: Lehigh UniversityInventor: Bryan William Berger
-
Patent number: 9539138Abstract: A method of micro-incision ophthalmic surgery, comprising, in the order mentioned, the steps of: (1) injecting a first viscoelastic substance through an incision site which is lateral to corneal into an anterior chamber which is in an opposite part of the incision site with discharging aqueous humor; (2) injecting a second viscoelastic substance having higher surface tension than that of the first viscoelastic substance through the incision site into the remaining anterior chamber unfilled with the first viscoelastic substance; and (3) injecting a third viscoelastic substance having lower surface tension than that of the second viscoelastic substance through the incision site into an area of the anterior chamber which is filled with the first viscoelastic substance until the incision site is sealed with the already injected the second viscoelastic substance.Type: GrantFiled: January 29, 2009Date of Patent: January 10, 2017Assignees: SEIKAGAKU CORPORATION, SANTEN PHARMACEUTICAL CO., LTD.Inventor: Takao Tanaka
-
Patent number: 9539227Abstract: The present invention relates to the novel use (anti-inflammatory activity) of Ramalin isolated from the Antarctic lichen Ramalina terebrata, and more specifically to a pharmaceutical composition containing Ramalin as an active ingredient. Ramalin of the invention is a compound derived from natural material, has no toxicity or side effects, and inhibits the expression of inducible nitric oxide synthase (iNOS) in the transcription stage to significantly inhibit the production of nitric oxide (NO) that is a key mediator of inflammatory responses. In addition, it inhibits the activation of the inflammatory mediator NF-?B, inhibits p38 MAPK, ERK1/2 and JNK signaling pathways, and inhibits the expression of the LPS receptor TLR4, suggesting that Ramalin has an excellent anti-inflammatory effect. Thus, the composition containing Ramalin can be effectively used to fundamentally treat or prevent inflammatory diseases or immune diseases and to relieve or alleviate the symptoms of the diseases.Type: GrantFiled: April 25, 2014Date of Patent: January 10, 2017Assignee: KOREA OCEAN RESEARCH AND DEVELOPMENT INSTITUTEInventors: Joung Han Yim, Il Chan Kim, Sung Gu Lee, Doc Kyu Kim, Se Jong Han, Hyoung Seok Lee, Sung Jin Kim, Tai Kyoung Kim, Pil-Sung Kang, Heeyong Park, Ha Ju Park, Suhkneung Pyo, Babita Paudel-Bhattarai
-
Patent number: 9539281Abstract: The invention provides compositions comprising lipid-conjugated forms of capsular polysaccharide A (PSA) from B. fragilis (referred to herein as PSA-LT), methods of isolating such forms and of making such compositions and methods for their use.Type: GrantFiled: July 12, 2012Date of Patent: January 10, 2017Assignee: The Brigham and Women's Hospital, Inc.Inventors: Dennis L. Kasper, Deniz Erturk-Hasdemir, Barbara Reinap
-
Patent number: 9540454Abstract: The present invention provides a high purity heparin useful to be a pharmaceutical product, cosmetics, research reagent, or the like, and a method for producing the same, more specifically, a heparin which does not substantially contain a nitrous acid degradation-resistant impurity and a method for producing a heparin, comprising mixing an aqueous solution of 5 to 30% by weight of the heparin with ethanol having an amount (volume) 0.2 to 1 times the amount (volume) of the aqueous heparin solution to obtain a colloidal precipitate of heparin.Type: GrantFiled: December 10, 2014Date of Patent: January 10, 2017Assignees: UNIVERSITY OF MIYAZAKI, FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Michio Muguruma, Hiroshi Murata
-
Patent number: 9522187Abstract: The present invention relates to methods of using neutral soluble glucan and monoclonal antibodies for antitumor therapy. Neutral soluble Beta (1,3; 1,6) glucan (NSG) enhances the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. The glucan does not stimulate the induction of inflammatory cytokines. Also described are methods of using whole glucan particles (WGP) as an immunomodulator by inducing a shift from a Th2 response to the Th1 response, leading to an enhanced antitumor cytotoxic T-cell response.Type: GrantFiled: October 30, 2014Date of Patent: December 20, 2016Assignee: University of Louisville Research Foundation, Inc.Inventor: Gordon D. Ross
-
Patent number: 9504722Abstract: The present invention discloses the extracts of Holoptelea integrifolia or the purified fractions isolated there from and the dietary, nutraceutical and pharmaceutical compositions comprising the same or optionally in combination with one or more known anti-obesic agents useful for the purpose of inhibition, amelioration or prevention of adipogenesis and lipolysis involved diseases. The invention further discloses a method for treating or preventing obesity and adipogenesis and lipolysis involved diseases using the compositions containing the extracts of purified fractions of Holoptelea integrifolia.Type: GrantFiled: August 20, 2007Date of Patent: November 29, 2016Assignee: Laila NutraceuticalsInventors: Ganga Raju Gokaraju, Rama Raju Gokaraju, Trimurtulu Golakoti, Krishanu Sengupta, Kiran Bhupatiraju
-
Patent number: 9492459Abstract: The present invention relates to a novel pharmaceutical composition of Linezolid. The present invention relates to a novel pharmaceutical composition comprising Linezolid Form III along with pharmaceutically acceptable excipients and a process to prepare the said composition. The present invention relates to an oral dosage forms for the treatment of severe infections caused by Gram-positive bacteria.Type: GrantFiled: August 2, 2013Date of Patent: November 15, 2016Assignee: Indoco Remedies LimitedInventors: Aditi Panandikar, Sundeep Bambolkar, Kavita Inamdar, Sapna Ramesh, Amol Burkul, Nasir Shaikh
-
Patent number: 9492474Abstract: The present invention provides compositions comprising hyaluronan with high elasticity, as well as methods for improving joint function, reducing pain associated with joint function and treating osteoarthritis by introducing into a joint a therapeutically effective amount of a composition comprising hyaluronan with high elasticity.Type: GrantFiled: July 9, 2014Date of Patent: November 15, 2016Assignee: Matrix Biology InstituteInventors: Endre A. Balazs, Carlos Belmonte
-
Patent number: 9474805Abstract: The present invention relates to a compound which is a polysaccharide derivative of GCSF, or of a GCSF like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.Type: GrantFiled: May 22, 2015Date of Patent: October 25, 2016Assignee: Lipoxen Technologies LimitedInventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis
-
Use of an active principle derived from and rich in linear galactans for controlling skin cell aging
Patent number: 9463149Abstract: A cosmetic active principle produced by the hydrolysis of Eucheuma cottonii and including linear galactans, as well as to the use thereof for promoting the protection of the telosome and telomeres of skin cells and thereby preventing and/or controlling skin aging. Also, the cosmetic compositions including the active principle and a cosmetic skincare method.Type: GrantFiled: February 6, 2013Date of Patent: October 11, 2016Assignee: SOCIETE INDUSTRIELLE LIMOUSINE D'APPLICATION BIOLOGIQUEInventor: Jean Paufique -
Patent number: 9463162Abstract: Kits and compositions for producing an alginate gel are disclosed. The kits and compositions comprise soluble alginate and insoluble alginate/gelling ion particles. Methods for dispensing a self-gelling alginate dispersion are disclosed. The methods comprise forming a dispersion of insoluble alginate/gelling ion particles in a solution containing soluble alginate, and dispensing the dispersion whereby the dispersion forms an alginate gel matrix. The methods may include dispensing the dispersion into the body of an individual. An alginate gel having a thickness of greater than 5 mm and a homogenous alginate matrix network and homogenous alginate gels free of one or more of: sulfates citrates, phosphates, lactatates, EDTA or lipids are disclosed. Implantable devices comprising a homogenous alginate gel coating are disclosed. Methods of improving the viability of pancreatic islets, or other cellular aggregates or tissue, following isolation and during storage and transport are disclosed.Type: GrantFiled: May 28, 2014Date of Patent: October 11, 2016Assignee: FMC Biopolymer ASInventors: Jan Egil Melvik, Michael Dornish, Edvar Onsoyen, Astrid B. Berge, Terje Svendsen
-
Patent number: 9456965Abstract: The present invention is an oil-in-water emulsified skin cosmetic comprising acetylated hyaluronic acid, a specific polymethacryloyloxyethyl phosphorylcholine derivative, non-emulsifying cross-linked silicone, glycerin, polyvinyl alcohol, an acrylamide type thickener, and an oil component in an amount of 25 wt % or more relative to the total amount of the oil-in-water emulsified skin cosmetic. The object of the present invention is to provide an oil-in-water emulsified skin cosmetic manifesting superior effects in improving spreadability on the skin, absorption in the skin, absence of stickiness, emollient sensations, taut sensations, and wrinkles/sagging.Type: GrantFiled: November 22, 2012Date of Patent: October 4, 2016Assignee: SHISEIDO COMPANY, LTD.Inventor: Takayuki Omura
-
Patent number: 9452224Abstract: Derivatives are synthesized of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde group. Where the polysaccharide has a sialic acid unit at the non-reducing end it may be passivated, for instance by converting into hydroxyl-substituted moiety. The derivatives may be reacted with substrates, for instance containing amine or hydrazine groups, to form non-cross-linked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs peptides or proteins or drug delivery systems.Type: GrantFiled: January 15, 2014Date of Patent: September 27, 2016Assignee: LIPOXEN TECHNOLOGIES LIMITEDInventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Dale Howard Hreczuk-Hirst, Ioannis Papaioannou
-
Patent number: 9446136Abstract: The present application provides compositions comprising hyaluronic acid having low levels of functional group modification, mixtures formed by controlled reaction of such lightly modified hyaluronic acid with suitable difunctional or multi-functional crosslinkers, and hydrogel precursor compositions and the resulting hydrogels. The compositions are lightly cross-linked and possess low pro-inflammatory properties when injected in vivo, and can be used as, for example, medical devices, biomedical adhesives and sealants, and for localized delivery of bioactive agents, among other uses.Type: GrantFiled: October 30, 2015Date of Patent: September 20, 2016Assignee: Carbylan Therapeutics, Inc.Inventors: David M. Gravett, George Y. Daniloff, Pingren He
-
Patent number: 9446093Abstract: The present invention is directed to the provision of an ophthalmic composition suitable for intravitreal injection. The composition includes an amount of complexing agent that reacts with one or more endogenous components (e.g., hyaluronic acid) in the eye to form a mass of enhanced viscosity. This mass can aid in creating a desirable release profile of therapeutic agent.Type: GrantFiled: October 18, 2013Date of Patent: September 20, 2016Assignee: Alcon Research, Ltd.Inventors: Masood A. Chowhan, Thomas C. Hohman, Ernesto J. Castillo, Wesley Wehsin Han
-
Patent number: 9439981Abstract: The present invention concerns a method for inducing an increase in the intraocular pressure in an animal, said method comprising ocular administration of a solution comprising benzalkonium chloride (BAK). The present invention further relates to an animal having ocular hypertension, said animal being obtained by the method according to the invention. Said animal provides a convenient animal model for better understanding of the patho-physiological mechanisms involved in ocular hypertension and glaucoma. The present invention also relates to the use of said animal for screening a compound for therapeutic use against ocular hypertension or glaucoma, and/or for assessing potential side-effects of treatment of ocular hypertension and glaucoma.Type: GrantFiled: July 27, 2012Date of Patent: September 13, 2016Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE VERSAILLES SAINT-QUENTIN-EN-YVELINESInventors: William Rostene, Christophe Baudouin, David Godefroy, Alexandre Denoyer